Printer Friendly

PROTEIN DESIGN LABS ANTIBODIES GRANTED ORPHAN DRUG STATUS

 MOUNTAIN VIEW, Calif., June 3 /PRNewswire/ -- Protein Design Labs Inc. (PDL) (NASDAQ: PDLI) said today that its human antibodies against cytomegalovirus (CMV) and hepatitis B have been granted orphan drug status for certain indications.
 The company said the U.S. Food and Drug Administration (FDA) has designated PDL's human anti-CMV antibody an orphan drug for treatment of CMV retinitis in AIDS patients and for prevention of CMV infections in patients undergoing organ transplantation. Orphan status has also been obtained for PDL's anti-hepatitis B antibody for prophylaxis of hepatitis B reinfections in patients undergoing liver transplantation secondary to end-stage chronic hepatitis B infection. Phase I/II clinical trials have been completed for each of these indications.
 Orphan drug status confers seven years of marketing exclusivity on products with a given molecular structure that serve patient populations of less than 200,000. The designation, which also gives certain potential tax benefits to the manufacturer, takes effect in the event the product is the first molecule with this structure to win marketing approval by the FDA.
 Results of a Phase I/II clinical trial with the human anti-CMV antibody for treatment of CMV retinitis in 17 AIDS patients will be presented on June 10 at the 9th International Conference on AIDS in Berlin. Exclusive rights to this antibody, to the human anti-hepatitis B antibody, and to three other antibodies were acquired by PDL from Sandoz Pharma Ltd. and Sandoz Pharmaceuticals Corp. in April.
 Protein Design Labs, founded in 1986, is engaged in the development of next-generation antibodies and other novel proteins to treat various disease conditions, including viral infections, autoimmune and inflammatory diseases and cancer.
 The company has four potential products in clinical trials and two core proprietary antibody technologies. PDL uses computer modeling techniques to combine the binding site of a mouse antibody with a large part of a human antibody. The resulting SMART Antibodies, which are more than 90-percent human, retain high binding affinity for the target antigens and will, PDL believes, substantially reduce or avoid the human anti-mouse antibody (HAMA) response that has limited the use of mouse monoclonal antibodies as human therapeutics. Two SMART Antibodies are in human clinical trials.
 PDL's second antibody technology is for development of human antibodies against viruses. The technology has been used to create human antibodies against CMV, hepatitis B, the herpes simplex virus and the varicella zoster virus (VZV). The human antibodies against herpes simplex and VZV are in preclinical development.
 -0- 6/3/93
 /CONTACT: Peter Dworkin, director, Corporate Communications of PDL, 415-903-3721/
 (PDLI)


CO: Protein Design Labs Inc. ST: California IN: MTC SU:

SG-GT -- SJ002 -- 4720 06/03/93 07:00 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jun 3, 1993
Words:441
Previous Article:TELECOMMUNICATIONS GAMING SIMULATOR VIRTUAL REALITY JOINT-MARKETING ANNOUNCED AT CES BY INTERACTIVE TECHNOLOGY MAJORS
Next Article:TANGER COMPLETES SUCCESSFUL INITIAL OFFERING; FIRST SHARES TRADE ON NYSE
Topics:


Related Articles
SMART ANTI-TAC ANTIBODY ENTERS INTERNATIONAL THIRD CLINICAL TRIAL
PDL MEETS MANUFACTURING MILESTONE, MAKES DRUG SUBSTANCE FOR CLINICAL TRIALS
PROTEIN DESIGN LABS ANTIBODIES SHOW TWO-WEEK HALF-LIFE IN PRIMATE STUDIES
PROTEIN DESIGN LABS APPOINTS MARK YOUNG VICE PRESIDENT, TECHNICAL OPERATIONS
Protein Design Labs Grants Humanization Patent License To NeoRx
Protein Design Labs Issues License Under Antibody Humanization Patents To Tanox
Protein Design Labs and Genentech Announce Agreement for Antibody Patents.
Inhibitex Awarded FDA Grant for the Clinical Development of Veronate(R).
Protein Design Labs Sublicenses Rights to Develop Antibody-Drug Conjugates for Prostate Cancer to Genentech, Inc.
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters